Smile Doctors and Dental Monitoring Expand and Accelerate Partnership to Provide Remote Monitoring to All Patients During the State of Emergency
Smile Doctors, the largest US based Orthodontic DSO (Dental Support Organization), with over 220 locations in 17 States, has signed a deal with Dental Monitoring to use its suite of AI powered remote monitoring solutions to provide industry leading patient access and convenience. Importantly, the original partnership agreed after several months of pilots and testing, has been expanded and accelerated to include all patients eligible with immediate effect this week, due to the Coronavirus national situation. All eligible Smile Doctors patients will therefore be able to start or continue their treatment remotely with Dental Monitoring.
Dental Monitoring will provide access to and training for all Smile Doctors specialist orthodontist clinics nationwide to all DM products, including SmileMate, Vision and Dental Monitoring.
- SmileMate enables virtual consultations with prospective new patients at home, offering an almost instant oral health assessment through photos taken with the patient’s own smartphone.
- Vision uses AI to produce within seconds an instant simulation of the patient’s face with different orthodontic appliances and also generates state-of-the-art simulation of post-treatment smiles, using the actual details of the patient’s teeth and gums, helping the patient choose their treatment with more confidence.
- Dental Monitoring uses AI to allow the Doctor to remotely monitor the progress of the patient’s treatment through photos taken by the patient using the DM app on their own smartphone, with a DM ScanBox. The Dental Monitoring solution allows real time communication between the Doctor’s team and the patient.
Commenting on the deal, CEO of Smile Doctors, J. Hedrick explained: “I am delighted to have achieved this partnership with Dental Monitoring, which I am certain will be to the extreme benefit to all of our patients. Dental Monitoring’s AI technology and patient user experience is second to none, and has brought dentistry up to speed with patients’ expectations in a digital world. The initial reception by both clinical team and patients in our pilots has been extremely positive, and we believe we have a unique differentiator in our offering to our Smile Doctors patients.”
CEO and Co-Founder of Dental Monitoring, Philippe Salah, added: “Smile Doctors for us is the ideal partner as we accelerate our growth in the US. We have established a true partnership where we will help Smile Doctors to fully utilize the full suite of DM products. We enable their orthodontists to address the needs of new patients, allow more of them to say yes to treatment, and then monitor their treatment progress efficiently, using our DM proprietary AI engine.”
On the acceleration of the partnership due to the current Coronavirus crisis, J. Hedrick said: “We decided to fast track our implementation of DM full heartedly throughout our entire network to make sure we could continue to serve our patients with the best clinical care. Dental Monitoring has been a unique and essential partner for us, and we are excited to be rolling out this service at such speed to respond to the crisis. I am grateful to Philippe and the DM team for really working side by side with us on this 24/7 in the interests of our patients.”
About Dental Monitoring (www.dental-monitoring.com)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney. For more information, please visit www.dental-monitoring.com.
About Smile Doctors, LLC ( www.smiledoctors.com )
Smile Doctors, LLC is the largest orthodontic dental support organization with more than 200 affiliated practices in 17 states. Based in Georgetown, TX and founded by Dr. Scott Law, Scotte Hudsmith, Dr. Dana Fender, and Dr. Greg Goggans, Smile Doctors focuses exclusively on developing and growing affiliated orthodontic practices. Orthodontists can focus on patient care while receiving the support of experienced professionals who are committed to the growth and success of their practices. Support provided by Smile Doctors includes services related to operations, accounting, marketing, and revenue cycle. For more information, please visit www.smiledoctors.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005353/en/
Contact information
Contact Dental Monitoring: Charlotte Garzino c.garzino@dental-monitoring.com
Contact SmileDoctor: Jessica Lynch, VP Operations - Jessica.Lynch@smiledoctors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom